Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › CT-388

CT-388

GIP/GLP-1 · s.c. · Roche

Data cut 12 November 2026 · page built 16 November 2026 · 2 trial arms · 2 trials with results · 5 registered trials · see on the pipeline board

Summary

Also known as
Roche / Carmot
Mechanism
GIP/GLP-1
Route
s.c.
Company
Roche
Highest development stage
phase 3
Status (as of data cut)
Phase 3 (Enith1, Enith2 and a third trial) recruiting since Mar 2026; phase 2 (48 weeks) presented at EASD 2026 verify
Next milestone
Phase 3 results (primary completion 2028)

Sources for the status

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
CT-388 phase 2CT-388 24 mgobesity48—−22.7 % vs −0.2 %
Δ −22.5 pp
————————verified
CT-388-104 (T2D)enicepatide 24 mgt2d48———−15.5 %
estimand not specified
−2.6——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (2)
  • CT-388 24 mg · weight_eff · Conclusion
    CT-388 demonstrated significant, dose-dependent WL of up to 22.7%
  • enicepatide 24 mg · weight_unsp · company announcement
    The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5

Registered trials (5)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
Enith-MACE
A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease
CV outcomesPhase 3not yet recruiting2027-01 → 2031-038200not yet recruitingNCT07918846
ENI-SPIRE-2
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
T2DPhase 3not yet recruiting2026-12 → 2029-04948not yet recruitingNCT07889648
NCT07670416 · China
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
ObesityPhase 3recruiting2026-07 → 2028-02300recruitingNCT07670416
Enith1
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
ObesityPhase 3recruiting2026-03 → 2028-072000recruitingNCT07351045
Enith2
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
ObesityPhase 3recruiting2026-03 → 2028-081600recruitingNCT07351058

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: CT-388. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/ct-388/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.